Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the United Kingdom and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

British Journal of Dermatology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2OgoUcm